Uncategorized

Biophytis SA announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting.

Biophytis SA announces its financial results for the year ended December 31, 2022, and provides updates on key perspectives for 2023.

AbbVie announced that the U.S. Food and Drug Administration has approved expanding the indication of QULIPTA® for the preventive treatment of migraine in adults.

Carbios has accelerated its enzyme screening process with a microfluidic technology developed in partnership with the Paul Pascal Research Centre.

Lucid Diagnostics Inc. announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.

Transgene and NEC Corporation announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research Annual Meeting in Orlando, Florida.

GC Genome Corporation, a leading diagnostics company, announced that the company will present data showcasing the deep learning algorithm that detects and classifies multi-cancer using methylation information and genomic data at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.

OSE Immunotherapeutics SA announces three presentations at the American Association for Cancer Research Annual Meeting in Orlando, April 14-19, 2023.

Glucose monitoring is a key link in diabetes management. Currently, there are two main methods for self-monitoring of glucose in patients with diabetes, one is the traditional blood glucose Monitoring, and the other is continuous glucose monitoring.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, is pleased to announce its participation in two investor conferences in April 2023.